NEW YORK, Sept 10 – Atugen, a Berlin-based functional genomics company, said Monday that Arena Pharmaceuticals had agreed to evaluate its G-protein coupled receptor technology.

Under the terms of the deal, Atugen’s US-based subsidiary will receive central nervous system gene targets from Arena for evaluation using its GeneBlocs gene expression technologies. The company will then try to determine gene function in vivo.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.